Previous Article | Next Article 
Journal of Virology, May 2000, p. 4273-4283, Vol. 74, No. 9
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Rescue of Multiple Viral Functions by a Second-Site
Suppressor of a Human Immunodeficiency Virus Type 1 Nucleocapsid
Mutation
Andrea
Cimarelli,1
Sara
Sandin,2
Stefan
Höglund,2 and
Jeremy
Luban1,3,*
Departments of
Microbiology1 and
Medicine,3 Columbia University College
of Physicians and Surgeons, New York, New York 10032, and
Department of Biochemistry, Biomedical Center, Uppsala,
Sweden2
Received 30 November 1999/Accepted 25 January 2000
 |
ABSTRACT |
Human immunodeficiency type 1 (HIV-1) bearing the nucleocapsid (NC)
mutation R10A/K11A is replication defective. After serial passage of
the mutant virus in tissue culture, we isolated a revertant that
retained the original mutation. It had acquired, in addition, a new
mutation (E21K) that was formally demonstrated to be sufficient for
restoration of viral replication. Detailed analysis of the replication
defect of R10A/K11A revealed a threefold reduction in virion yield and
a fivefold reduction in packaging of viral genomic RNA. Real-time PCR
was then used to quantitate viral DNA synthesis following infection of
Jurkat T cells. After adjustment for the assembly and packaging
defects, a minor (twofold) reduction in synthesis of either
strong-stop, full-length linear DNA or 2-LTR circles was observed with
R10A/K11A virions, indicating that reverse transcription and nuclear
transport of the viral genome were largely intact. However, after
adjustment for the amounts of full-length or 2-LTR circles produced,
R10A/K11A virions were at least 10-fold less infectious than wild type,
indicating that viral DNA produced by the R10A/K11A mutant failed to
integrate. Each of the above-mentioned defects was corrected by
introduction of the second-site compensatory mutation E21K. These
results demonstrate that the replication defect of mutant R10A/K11A can
be explained by impairment at multiple steps in the viral life cycle,
most important among them being integration and RNA packaging. The E21K
mutation is predicted to restore positive charge to the face of the
R10A/K11A mutant NC protein that interacts with the HIV-1 SL3 RNA
stem-loop, emphasizing the importance of NC basic residues for HIV-1 replication.
 |
INTRODUCTION |
Retroviral nucleocapsid (NC)
proteins are expressed as part of a Gag polyprotein precursor which is
cleaved by the virus-encoded protease during virion maturation
(reviewed in references 29 and
47). With the exception of spumaviruses, NC proteins
encoded by different retroviruses share two structural characteristics: the presence of either one or two Cys-His box motifs
(Cys-X2-Cys-X4-His-X4-Cys) and a
large number of basic residues distributed throughout the protein
(reviewed in references 5 and
63).
NC plays roles in nearly all steps of the viral life cycle. As a domain
within the Gag polyprotein, NC specifically binds and incorporates
viral genomic RNA into virions (reviewed in references 5 and 63) and drives virion
assembly by promoting interaction among Gag polyproteins (4, 11,
14, 17a, 28, 34, 42, 54, 67). Within the nascent virion, after
cleavage from the Gag polyprotein, NC coats viral genomic RNA and
promotes its maturation into a more stable dimeric form (26, 27,
30, 31). Upon infection of a susceptible target cell, NC
contributes to reverse transcription (RT) (1, 2, 39, 49, 59, 62,
68, 71). NC may also facilitate integration of viral DNA into
host cell chromosomal DNA, either by facilitating the
integrase-mediated strand transfer or by relieving DNA secondary
structure, as suggested by in vitro studies (15, 16, 48). It
has been difficult to confirm the in vitro effects of NC on integration
in vivo since many NC mutations decrease RNA packaging or directly
inhibit the efficiency of RT. The effect of these mutations is to limit
the yield of viral DNA synthesized after infection to levels too low for meaningful analysis of subsequent events. Recently, however, Moloney murine leukemia virus (M-MuLV) NC mutations have been shown to
block a step in the replication cycle that follows nuclear entry of
viral DNA, suggesting that NC plays a role in integration in vivo
(36).
All of NC's varied functions appear to depend on its ability to bind
RNA (for reviews, see references 5, 19, and
63). Both Cys-His boxes and basic residues are
determinants of NC's interaction with RNA, the former providing
specificity for interaction with viral genomic RNA and the latter
providing nonspecific association with nucleic acid (21).
Though NC Cys-His boxes have received a great deal of attention, the
basic residues, through their nonspecific RNA-binding activity, mediate
many of NC's functions, as mutation of human immunodeficiency virus
type 1 (HIV-1) NC basic residues can disrupt RNA packaging (6,
17a, 58, 60), virion assembly (17a, 20), and RT
(6, 40).
In this study, we report the isolation of a viral revertant of a
replication-defective mutant in which two basic residues at the N
terminus of HIV-1 NC are replaced by alanine (R10A/K11A). We show that
the phenotypic reversion is due to the presence of a second-site
compensatory mutation (E21K). Detailed characterization of the
R10A/K11A mutant shows that there are multiple defects throughout the
viral life cycle, ranging from genomic RNA packaging to integration of
viral DNA. Each of the defects is corrected to a considerable extent by
the presence of the E21K mutation.
 |
MATERIALS AND METHODS |
Plasmid DNAs.
The HIV-1 proviral construct R10A/K11A is
described elsewhere (17a). This construct, as well as all
the proviral constructs used in this study, are chimeric proviral DNAs
in which an SphI/EcoRV fragment in NL4-3 that
spans the NC coding sequence has been replaced by the corresponding
fragment of HXB-2 (nucleotides 1443 to 2977, according to reference
57). Mutation E21K was introduced de novo into
mutant and wild-type proviral DNAs by mutagenic PCR, according to
standard procedures and using oligonucleotides
5'-CAATTGTGGCAAAAAAGGCCACACAGCCAG-3' (nucleotides 1965 to
1994) and 5'-CTGGCTGTGTGGCCTTTTTTGCCACAATTG-3' (nucleotides
1994 to 1965). The products obtained after mutagenic PCR were digested
with SphI/ApaI (nucleotides 1443 to 2001) and used to replace the corresponding fragments of R10A/K11A or wild-type proviral DNAs. Fragment sequences were confirmed by dideoxy sequencing.
Cell lines.
The human T-lymphocyte cell line Jurkat
(69) was maintained in RPMI 1640 supplemented with 10%
fetal bovine serum (FBS). Human 293T and HeLa fibroblasts were
maintained in Dulbecco modified Eagle medium (DMEM) supplemented with
10% FBS. HeLa-CD4-LTR-
-gal (obtained through the AIDS Research and
Reference Reagent Program; catalog no. 1470) were maintained in DMEM
supplemented with 10% FBS, 0.2 mg of G418 per ml, and 0.1 mg of
hygromycin B per ml; this cell line expresses CD4 and contains a
-galactosidase (
-Gal) gene under the control of HIV-1 long
terminal repeat (LTR) (45).
Viral replication assay.
Viral infections were initiated in
106 Jurkat cells by DEAE-dextran (250 µg/ml; Pharmacia
Biotech Inc., Piscataway, N.J.), using 2 µg of proviral DNA in 1 ml
of serum-free RPMI 1640 for 20 min at room temperature. Cells were then
washed in serum-free medium and resuspended in 3 ml of conditioned
medium. Every 2 days supernatant was harvested and frozen, and cells
were passaged. At the conclusion of the experiment, the stored samples
were analyzed for exogenous RT activity as described below.
Exogenous RT assay.
Cell culture supernatant (10 µl) was
added to 50 µl of RT cocktail {60 mM Tris-HCl (pH 8.0), 180 mM KCl,
6 mM MgCl2, 6 mM dithiothreitol (DTT), 0.6 mM EGTA, 0.12%
Triton X-100, 6 µg of oligo(dT) and 12 µg of poly(rA) per ml, 0.05 mM [
-32P]dTTP (800 Ci/mmol)} for 1 h at 37°C;
2 µl was spotted onto DEAE-81 paper and washed three times with 2×
SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate)
(64). A PhosphorImager (Molecular Dynamics, Sunnyvale,
Calif.) was used to quantify the radioactivity incorporated.
Molecular cloning of an R10A/K11A revertant.
RNA was
extracted from 100 µl of supernatant containing revertant virions at
the peak of infection, using an RNAzol B isolation kit (Tel-Test Inc.,
Friendswood, Tex.) as instructed by the manufacturer. RNA was reverse
transcribed for 1 h at 37°C using 200 ng of random primers
(Stratagene, La Jolla, Calif.), 20 U of RNAsin inhibitor, 40 U of
M-MuLV reverse transcriptase (Gibco-BRL, Rockville, Md.), 50 mM Tris-Cl
(pH 8.3), 40 mM KCl, 6 mM MgCl2, 1 mM DTT, and 260 µM
deoxynucleoside triphosphates (dNTPs) in a total volume of 30 µl.
One-tenth of the RT reaction was amplified using Pfu DNA polymerase (Stratagene, La Jolla, Calif.) and primers specific for the
gag region: 5'-ATGGGTGCGAGAGCGTCGG-3'
(nucleotides 788 to 806) and 5'-CTTTATTGTGACGAGGGGTCGC-3'
(nucleotides 2291 to 2270). PCR products were blunt cloned into
pBluescript that had been linearized with EcoRV.
Metabolic labeling and immunoprecipitation.
HeLa cells in
35-mm-diameter plates were transfected with proviral DNAs by using
calcium phosphate as previously described (17a). Forty-eight
hours posttransfection, cells were incubated for 1 h at 37°C
with 2 ml of DMEM lacking methionine and cysteine prior to a 45-min
pulse with 100 µCi of [35S]Met/Cys (Translabel; ICN) in
500 µl. Cells were washed with phosphate-buffered saline (PBS),
incubated with complete DMEM, and lysed 0, 1, 3, and 6 h later in
radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 1% NP-40,
0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 50 mM Tris-Cl
[pH 8.0]). Virions were purified from the supernatant by
ultracentrifugation for 2 h at 80,000 × g through
a cushion of 25% sucrose (wt/vol); the pellet was resuspended in RIPA
buffer. Cell lysate- and virion-associated fractions were incubated
with 100 µl of protein A-Sepharose beads (Sigma; 10% slurry in RIPA
buffer) for 1 h at 4°C. Supernatant was removed from the beads
and incubated with 25 µg of total immunoglobulin from an
HIV-1-infected individual (serum obtained from the AIDS Research and
Reference Reagent Program; catalog no. 3957) for 2 h at 4°C.
Protein A-Sepharose beads (100 µl) were then added for 1 h at
4°C. Beads were washed three times, and proteins bound to the beads
were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) and
PhosphorImager quantification.
Analysis of HIV-1 virion morphology by electron microscopy.
Jurkat cells were transfected with HIV-1 proviral DNAs, and the
infections were allowed to proceed for 14 days. Cells were then fixed
with freshly made 2.5% glutaraldehyde in phosphate buffer (pH 7.0).
Cells were postfixed in 1% osmium tetroxide and then embedded in Epon.
Poststaining was done with 1% uranyl acetate. Sections were cut
approximately 60 nm thick to accommodate the volume of the core
structure parallel to the section plane. Specimens were analyzed with a
Zeiss CEM 902 electron microscope, equipped with a spectrometer to
enhance image contrast, at an accelerating voltage of 80 kV. A liquid
nitrogen-cooling trap of the specimen holder was used throughout. For
each mutant, a series of electron micrographs was used for the
statistical evaluation of the classes of different morphology present
in the sample; 90 to 300 particles were evaluated for each sample.
Dot blot analysis.
Dot blot analysis was performed as
previously described (17a). Briefly, virions produced by
calcium phosphate transfection of 293T cells were purified by
ultracentrifugation through 25% sucrose (wt/vol), resuspended, and
normalized by exogenous RT activity. Virions were then transferred to a
nylon membrane using a dot blot apparatus (Bio-Rad). The membrane was
hybridized overnight at 42°C in 10% polyethylene glycol, 1.5× SSPE
(1× SSPE is 0.18 M NaCl, 10 mM NaH2PO4, and 1 mM EDTA [pH 7.7]), 7% SDS, 100 µg of salmon sperm DNA per ml with
a 32P-end-labeled DNA oligonucleotide
(5'-CTGACGCTCTCGCACCC-3', antisense nucleotides 808 to 792 from pNL4-3) that hybridizes with HIV-1 genomic RNA (53).
The membrane was washed in 0.1% SDS-0.2× SSC and analyzed with a PhosphorImager.
Endo-RT assay.
Endogenous RT (endo-RT) reactions were
performed as previously described (35). Briefly, particles
in supernatant obtained from transfection of four 293T cell plates
(100-mm diameter) were purified by ultracentrifugation through 25%
sucrose at 80,000 × g as previously described
(17). Virions were resuspended in PBS for 12 to 18 h on
ice and normalized by exogenous RT assay. Virions thus normalized were
permeabilized by addition of 5 mM
-octylglucoside for 10 min at room
temperature. After the permeabilization step, the reaction mixture was
made 50 mM Tris-HCl (pH 8.4), 2 mM DTT, 2 mM magnesium acetate, 0.1 mM
each dATP, dGTP, and dCTP, and [32P]TTP (12 Ci/mmol) and
incubated overnight at 37°C in a total volume of 100 µl. Samples
were then treated for 1 h at 55°C with 0.5% SDS, 25 mM EDTA,
100 mM NaCl, tRNA (50 µg/ml), and proteinase K (20 µg/ml), phenol
extracted, and ethanol precipitated. Samples were denatured in 0.3 M
NaOH for 30 min at 37°C and run on a 1% agarose gel. The gel was
dried and exposed for PhosphorImager analysis.
Real-time PCR analysis.
Infections were performed as
previously described (9). Jurkat cells (106)
were infected in a total volume of 200 µl of RPMI 1640 for 1 h
at 37°C. Medium, was added and cells were incubated 12 h at 37°C. Cell lysis for the isolation of low-molecular-weight DNA was
performed as previously described (9, 40). A portion (1/15)
of each DNA preparation was amplified in triplicate using 1× TaqMan
buffer A (Perkin-Elmer, Norwalk, Conn.), 3.5 mM MgCl2, molecular beacon (0.4 pmol/µl), primer (0.4 pmol/µl), and 1.25 U of
AmpliTaq Gold DNA polymerase (Perkin-Elmer) in a total volume of 50 µl. The sequence of molecular beacon (50) is
5'-FAM-GCGGGTTCTGAGGGATCTCTAGTTACCAGACCCGC-DABCYL-3' (underlined sequence corresponding to nucleotides 9675 to 9653), where
6-carboxyfluorescein (FAM) serves as the reporter fluorochrome and
4-dimethylaminophenylazobenzoic acid (DABCYL) serves as the quencher.
This molecular beacon recognizes both full-length proviral DNA and
2-LTR circles. One cycle of denaturation (95°C for 10 min) was
followed by 45 cycles of amplification (95°C for 15 s, 60°C
for 30 s, and 72°C for 30 s). PCR was carried out in a
spectrofluorometric thermal cycler (ABI PRISM 7700; Applied Byosystem
Inc.) that monitors changes in the fluorescence spectrum of each
reaction tube during the annealing phase while simultaneously carrying
out programmed temperature cycles. PCR primer pairs used to
specifically amplify full-length proviral DNA and 2-LTR circles were
5'-GCTAGTACCAGTTGAGCCAGATAAG-3' (nucleotides 9215 to 9239)
plus 5'-AGCAAGCCGAGTCCTGCGTC-3' (nucleotides 705 to 686) and
5'-GGTACTAGCTTGAAGCACCATCC-3' (nucleotides 149 to 127) plus
5'-GCCTCAATAAAGCTTGCCTTGAGTG-3' (nucleotides 9594 to 9618),
respectively. Each sample was normalized as described above with
primers and beacon specific for mitochondrial DNA (accession no.
J01415): 5'-CACAGCCACTTTCCACACAGACAT-3' (nucleotides 257 to
280), 5'-GATGCGATTAGTAGTATGGGAGTGGG-3' (nucleotides 485 to 459), and
5'-FAM-GCGCGGTGGGGTTTGGCAGAGATGTGCCGCGC-DABCYL-3'
(underlined sequence corresponding to nucleotides 357 to 337).
Single-round infectivity assay.
HeLa-CD4-LTR-
-gal cells
(45) were seeded 24 h before infection at 40,000 cells/well (12-well plate) in medium lacking drug for selection.
Infection was performed in 500 µl with DEAE-dextran (15 µg/ml). Two
hours postinfection, 1 ml of DMEM was added. After 2 days, cells were
washed with PBS and fixed with a freshly made solution of 1%
formaldehyde-0.2% glutaraldehyde in PBS for 5 min at room
temperature. Cells were again washed with PBS and incubated with 1 ml
of 4 mM potassium ferrocyanide, 4 mM potassium ferricyanide, 1 mM
MgCl2, and 0.4 mg of
5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-Gal)
per ml in PBS for 50 min in a non-CO2 incubator. Cells were
washed in PBS, and
-Gal-positive cells were counted in an optic microscope.
Computer modeling of NC structure.
Three-dimensional
coordinates for the nuclear magnetic resonance structure of NC
complexed with the SL3-RNA (21) were retrieved from the
National Center for Biotechnology Information database (PBD Id:1A1T).
Graphical display of the data was generated by using the computer
software program Insight II (Biosym/Molecular Simulation).
 |
RESULTS |
Isolation of a phenotypic revertant of the R10A/K11A mutant.
Previous studies demonstrated that mutation of multiple basic residues
in HIV-1 NC generally impairs viral replication in T-lymphocyte cell
lines (17a, 60). In an attempt to obtain phenotypic viral
revertants of such mutants, five viral DNAs bearing different NC
mutations were each transfected individually into Jurkat T cells. These
viral mutants ranged in severity from 2 to 10 basic residues
substituted with alanine (17a). After 60 days of passage, RT
activity was detected in the supernatant of Jurkat cells that had been
transfected with the R10A/K11A HIV-1 proviral DNA construct (Fig.
1). No other culture yielded evidence of
viral replication. To determine if the increase in exogenous RT
activity was due to the emergence of a phenotypic revertant, supernatant from this cell culture was used to infect fresh Jurkat cells. Upon retesting, virus grew with wild-type kinetics, suggesting the presence of a revertant virus (data not shown).

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of the major domains of the
HIV-1 Gag polyprotein. Amino acid sequences of wild-type and mutant NC
proteins are given below. Dashes indicate amino acid identity with the
wild type. Cys-His boxes are underlined. MA, matrix; SP, spacer.
|
|
A second-site suppressor mutation (E21K) is sufficient to rescue
replication of the R10A/K11A mutant.
To determine the genetic
basis for phenotypic reversion, the entire gag coding
sequence was analyzed. Viral genomic RNA was extracted from virions,
reverse transcribed, and amplified by PCR using primers that allowed
amplification of the entire gag gene. The PCR product was
ligated into a plasmid, and the complete gag coding
sequences of several individual clones were determined. All clones
contained the original R10A/K11A NC mutation, indicating that
phenotypic reversion was not explained by a reversion mutation or by
contamination with wild-type virus. One clone contained a silent
mutation in CA (data not shown). A second-site mutation in NC (E21K)
was present in all clones (Fig. 1), suggesting that we had identified
the genetic basis for phenotypic reversion.
To determine if the second-site mutation in NC was responsible for the
observed phenotypic reversion, the E21K mutation was introduced de novo
into both wild-type and R10A/K11A mutant proviral DNA constructs.
Jurkat T cells were transfected with the proviral DNAs. Supernatant was
collected every 2 days, and exogenous RT activity was determined as an
indication of viral spread through the culture (Fig.
2). As expected, no detectable exogenous
RT activity was measured in the supernatant of Jurkat cells transfected with the R10A/K11A proviral DNA construct. In contrast, exogenous RT
activity accumulated with the same kinetics as the wild type when cells
were transfected with either R10A/K11A/E21K or E21K proviral DNA. These
results prove that the E21K mutation is sufficient to correct the
replication defect of mutant R10A/K11A.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 2.
Replication of HIV-1 wild type and NC mutants following
transfection of proviral DNAs into the Jurkat T-cell line. The
accumulation of RT activity in the cell culture supernatant (ordinate)
is shown for the indicated day posttransfection (abscissa).
|
|
Analysis of virion assembly kinetics.
Since NC plays roles in
practically all steps of the retroviral life cycle, we examined the
effect of the R10A/K11A double mutation and of the R10A/K11A/E21K
triple mutation on each of these steps. The effect of R10A/K11A on
viral replication has been partially characterized elsewhere (17a,
60). A decreased efficiency of virion release and the
accumulation of incompletely processed p25 (consisting of CA [capsid
protein] fused to the spacer peptide) has been found with R10A/K11A
(17a). To determine if virion assembly of R10A/K11A was
rescued by the E21K mutation, HeLa cells were transfected with
wild-type and R10A/K11A/E21K proviral DNAs and pulsed for 45 min with
[35S]Met/Cyst (Fig. 3).
Labeled proteins were chased for 0, 1, 3, and 6 h, and
cell-associated and virion-associated proteins were immunoprecipitated
with serum from an HIV-1-infected individual. Mutant R10A/K11A/E21K
assembled virions with kinetics similar to that of the wild type (Fig.
3), with normal accumulation of Gag-processing intermediates. The
magnitude of virion release was determined to be near normal when the
virion-associated CA signal at the 6-h time point was normalized to the
intensity of the cell-associated Gag polyprotein signal at the 0-h time
point (Table 1). These results
demonstrated that the defect in viral assembly of mutant R10A/K11A was
corrected by the second-site mutation E21K. Expression and processing
of env-encoded proteins was normal. Also, processing of
gag- and pol-encoded proteins at other sites
appeared normal, as judged by Western blot analysis (data not shown).

View larger version (79K):
[in this window]
[in a new window]
|
FIG. 3.
Pulse-chase analysis of HIV-1 NC wild type and
R10A/K11A/E21K mutant. HeLa cells transfected with the indicated
proviral DNAs were metabolically labeled with
[35S]Met/Cys for 45 min and chased for 0, 1, 3, 6 h,
as indicated. Virion-associated proteins were purified by
ultracentrifugation through 25% sucrose. Virion- and cell-associated
proteins were immunoprecipitated with sera from an HIV-1-infected
individual and analyzed by SDS-PAGE. Positions of mobility of the
envelope glycoprotein precursor (gp160), surface envelope protein
(gp120), Pr55Gag precursor (p55), incompletely processed
Gag precursors (p41 and p25), and completely processed CA (p24) are
indicated on the left.
|
|
Morphology of NC mutant virions.
Infection of Jurkat cells was
initiated by transfection of proviral DNAs; after 14 days, cells were
fixed and analyzed by electron microscopy. As expected, the majority
(96%) of wild-type virions exhibited mature, cone-shaped core
structures of high density (Fig. 4a); 3%
of wild-type particles exhibited immature morphology with a rim of
high-density material inside the envelope, and 1% exhibited an
irregular core structure. The majority of particles (79%) observed
with the R10A/K11A mutant were immature, with a characteristic rim of
high-density material present inside the envelope (Fig. 4b); 2% of
these virions had a dense, globular core structure in the center.

View larger version (129K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of virion morphology by electron microscopy.
Jurkat cells were transfected with proviral DNAs; 14 days later, cells
were fixed, stained, embedded, and visualized by electron microscopy.
(a) Mature wild-type virions showing a characteristic cone-shaped core
structure of high density. (b) Virus particles of mutant R10A/K11A
showing a rim of high-density material inside the envelope and
occasionally a dense, globular core structure in the center. (c)
Particles of mutant R10A/K11A/E21K showing a rim of high-density
material inside the envelope (left) and two globular core structures
(left, middle, and right). (d) Particles of mutant R10A/K11A/E21K
showing a cone-shaped core structure of high density (left). (e)
Particle of mutant E21K showing a dense, globular core structure in the
center. (f) Mutant E21K virions showing a cone-shaped core structure of
high density (left), a rim of high-density material inside the envelope
(middle), and two core structures of high density (right). (g)
Particles of mutant E21K showing two extended core structures of low
density (right), two to four globular core structures of high density
(left), and a rim of high-density material inside the envelope
(middle). The bar indicates 100 nm.
|
|
Consistent with the restored replicative capacity conferred by the
second-site suppressor mutation, 85% of R10A/K11A/E21K virions
exhibited a mature morphology with cone-shaped core structures of high
density (Fig. 4d). In addition, 13% of virion particles contained two
globular core structures of high density (Fig. 4c); 2% of the
R10A/K11A/E21K virions exhibited a dense, globular core structure in
the center.
When virions were produced by provirus bearing only the E21K mutation
in an otherwise wild-type background, 89% exhibited the morphology of
normal, mature virions (Fig. 4f), and 3% had a dense, globular core
structure in the center (Fig. 4e). Interestingly, 8% had two or as
many as four core structures of high density (Fig. 4g).
Effect of the second-site compensatory mutation on viral genomic
RNA incorporation into virions.
Viral genomic RNA incorporation
has been shown to be modestly impaired in R10A/K11A virions ((17a,
60). To determine if the second-site mutation restored viral
genomic RNA incorporation to normal levels, virions produced by
transfection of 293T cells with wild-type, R10A/K11A, or R10A/K11A/E21K
proviral DNAs were purified and normalized by exogenous RT
activity. The amount of viral genomic RNA incorporated was then
determined by dot blot analysis as previously described (17a,
52). Supernatant obtained from cells transfected with proviral
DNA coding for a myristylation-deficient Gag was used as a negative
control. The R10A/K11A mutation reduced RNA packaging to levels 22% of
that of the wild-type (Fig. 5 and Table
1) (17a, 60). The presence of the second-site mutation (R10A/K11A/E21K) increased the amount of viral genomic RNA incorporated into virions by approximately threefold compared to the R10A/K11A mutant (Fig. 5 and Table 1).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 5.
Viral genomic RNA incorporation into wild-type and
mutant virions. Virions produced by transfection of 293T cells with
proviral DNAs were purified by ultracentrifugation through 25%
sucrose, resuspended in PBS, and normalized by exogenous RT assay.
Normalized amount of virions were loaded onto a nylon membrane and
probed with a 32P-end-labeled DNA oligonucleotide specific
for viral genomic RNA. The signal obtained after hybridization was
quantified with a PhosphorImager. Results are presented as percentage
of wild-type virus activity. The bar graph presents results obtained
from three independent experiments with standard errors of the mean
(primary data from a representative experiment are shown underneath).
myr indicates a virion preparation from cells
transfected with a myristylation-deficient NL4-3.
|
|
Effect of the second-site mutation on endo-RT.
To determine if
impairment in viral replication was due to an intrinsic defect in the
RT reaction, endo-RT was examined next. Purified virions were
permeabilized with 5 mM
-octylglucoside and incubated for 24 h
at 37°C with unlabeled dNTPs plus [32P]TTP. Virions
were then treated with proteinase K, and nucleic acid was extracted and
precipitated. Samples were then run on an agarose gel. A band
corresponding to full-length viral DNA was observed in wild-type and
both mutant virions (Fig. 6). We also
observed a smear, containing degradation products and incomplete forms
of RT (8, 35, 44), constituting up to 90% of the total
radioactivity present in the lanes. Because of the smear, we considered
quantitation of the results relatively inaccurate, but a decrease
(about threefold) in the overall amount of endo-RT products was
observed in R10A/K11A virions relative to the wild type. For the
R10A/K11A/E21K mutant, the reduction in endo-RT product was slightly
less (about twofold). Similar results were obtained when virion
permeabilization was performed with 0.01% Triton X-100 (data not
shown).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 6.
Endo-RT in wild-type and mutant virions. After
purification through 25% sucrose and normalization by exogenous RT,
virions produced by transient transfection of 293T cells were
permeabilized with -octylglucoside and incubated with
[32P]TTP and unlabeled dNTPs. The products of endo-RT
were extracted with proteinase K, precipitated, and run on an agarose
gel prior to PhosphorImager analysis.
|
|
Quantitation of viral DNA synthesis after infection using real-time
PCR.
The effect of the NC mutations on the early steps of the
viral life cycle was studied by quantifying full-length linear viral DNA and 2-LTR circles synthesized after a single round of infection using real-time PCR. Virions normalized by exogenous RT were used to
infect Jurkat T cells. Low-molecular-weight DNA was harvested 12 h
postinfection. PCR was performed with primer pairs that amplify full-length linear DNA or 2-LTR circles. By exploiting nucleotide differences between the 5' and 3' LTRs of pNL4-3, the primers amplify
only newly synthesized viral DNA and not contaminating plasmid DNA
carried over from the transfection in which the virions were produced
(9). To ensure that there were equal amounts of sample DNA
added to each real-time PCR, mitochondrial DNA was amplified with
specific primers (9) and quantitated as described below with
a molecular beacon (see Materials and Methods for details).
To quantify the viral DNA template copy number in each sample, a
molecular beacon was used in combination with real-time PCR as
previously described (46, 50). The molecular beacon is an
oligonucleotide with a fluorochrome at one end and a quencher at the
other. It is designed to form a stem-loop structure that brings the
quencher in close proximity to the fluorochorome. As a result, little
signal is emitted when the beacon is in its folded conformation. The
loop is designed to hybridize with the amplified sequence, so that at
each annealing step, the molecular beacon anneals to the amplified
sequences. Consequently, with each PCR cycle increasing fluorescence is
emitted that is detected by a spectrofluorometric thermal cycler (ABI
PRISM 7700; Applied Biosystems Inc.).
For each experiment, a standard curve was generated by experimentally
determining the threshold cycle (CT) for known
template DNA copy number (in duplicate) ranging from 10 to
106 molecules. CT is the cycle
number at which the mean fluorescence rises 10 standard deviations
above the baseline. For either the full-length linear DNA (Fig.
7A) or the 2-LTR circles (data not shown), the CT was directly proportional to the
template input copy equivalents (Fig. 7A, inset).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 7.
Quantitation of steady-state viral DNA 12 h after
infection of Jurkat T cells. (A) Representative standard curve for the
quantitation of full-length viral DNA sequences using real-time PCR
with a molecular beacon. Change in fluorescence ( Rn) as a function
of cycle number is demonstrated for viral DNA plasmid copy numbers
ranging from 10 to 106 per reaction. The
CT is shown for duplicates of the standards
used. The inset shows the relationship between known input DNA copy
numbers and the CT. The
CT is directly proportional to the log of the
input copy equivalents, as demonstrated by the standard curve generated
(r2 = 0.992). (B and C)
Low-molecular-weight DNA was isolated from Jurkat cells after infection
with the indicated viruses (9, 40). Real-time PCR was
performed using primers specific for full-length (B) or circular 2-LTR
(C) viral DNA. Input copy number was determined as shown in panel A. Results are presented as percentage of wild-type viral DNA. The bar
graph presents results obtained from two independent experiments with
standard errors of the mean.
|
|
Copy number for each experimental sample was calculated by
interpolation from the experimentally determined
CT standard curve. At 12 h postinfection,
the steady-state level of full-length proviral DNA with mutant
R10A/K11A was 10% of the wild-type level (Fig. 7B and Table 1).
Considering the method that we used for normalizing virions, and
correcting for the fivefold reduction in RNA packaging, the actual
defect in RT with R10A/K11A was only twofold. An identical defect was
observed in the formation of 2-LTR circles by the R10A/K11A mutant
(Fig. 7C), suggesting that there was no measurable defect in nuclear
import of the preintegration complex. R10A/K11A/E21K accumulated nearly
wild-type levels of both full-length linear and 2-LTR DNAs (Fig. 7B and C).
Effect of NC mutants in the MAGI assay.
An indicator cell
line, HeLa-CD4-LTR-
-gal, bearing a
-Gal gene under the control of
the HIV-1 LTR (45), was used to determine the infectivity of
mutant virions in a single round of infection. Virions produced by
transfection of 293T cells were purified by ultracentrifugation through
25% sucrose, resuspended, and normalized by exogenous RT activity.
Normalized virions were used to infect HeLa-CD4-LTR-
-gal cells in
triplicate. Two days postinfection, cells were washed and fixed in
formaldehyde, and
-Gal-positive cells were counted.
Cells infected with different dilutions of virion stocks indicated that
the R10A/K11A mutant had 100-fold-lower titer than the wild type (Fig.
8). A 100-fold relative decrease in titer associated with the R10A/K11A mutation was observed whether the experiment was performed with virus stocks generated by transfection with complete provirus (Fig. 8) or with env-deleted
proviruses pseudotyped with vesicular stomatitis virus G protein
(VSV-G) (data not shown). This indicates that the observed
-Gal
activity was due to a single round of viral infection. Similar results were obtained when, instead of measuring
-Gal activity, we measured luciferase activity after infection with a VSV-G-pseudotyped virus in
which env had been replaced with a luciferase gene cassette (data not shown). Since full-length viral DNA and 2-LTR circles were
decreased 10-fold with the R10A/K11A mutant, these results indicate
that there is at least an additional 10-fold reduction in infectivity
due to disruption of postnuclear import processes such as integration.
As judged by the MAGI assay, the second-site mutation restored the
infectivity of mutant R10A/K11A/E21K virions almost to wild-type levels
(42%).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 8.
Infectivity of HIV-1 wild-type and NC mutant virions
after a single-round infection (MAGI assay). Virions produced by
transfection of proviral DNAs into 293T cells were purified by
ultracentrifugation through 25% sucrose. Virions were normalized by
exogenous RT and used to infect HeLa-CD4-LTR- -gal cells. Cells were
infected with the indicated amounts of wild-type and mutant virion
preparations. Infectious titers were determined by scoring the number
of -Gal-positive cells 2 days postinfection. Results are presented
as percentage of wild-type virus activity. The bar graph presents
results obtained from three independent experiments with standard
errors of the mean.
|
|
 |
DISCUSSION |
In this report we have described the detailed characterization of
HIV-1 NC mutant R10A/K11A and of a phenotypic revertant bearing a
second-site suppressor mutation (R10A/K11A/E21K). Given the many roles
of NC in the retrovirus life cycle, we examined the effect of our
mutants on steps spanning the entire replication cycle. By this
approach, we demonstrated that mutant R10A/K11A exhibits several,
distinct defects, the major ones being in integration and RNA packaging.
A defect in viral RNA packaging and virion assembly has been previously
reported for mutant R10A/K11A (17a, 60). These defects were
corrected in the revertant, although the level of RNA packaging in
R10A/K11A/E21K virions was still only 60% of the wild-type level. In
addition, a Gag-processing defect present in mutant R10A/K11A
(17a) was also corrected in R10A/K11A/E21K virions. The
biochemical analysis was supported by electron microscopy analysis
showing that R10A/K11A/E21K virions had wild-type morphology, while
R10A/K11A virions showed lack of core condensation, also as previously
reported (17a, 60).
Though the majority have immature morphology, R10A/K11A mutant virions
were still able to infect target cells and to complete RT. The
efficiency of RT was accurately quantitated using real-time PCR and
found to be 10-fold lower in mutant R10A/K11A than in the wild type or
R10A/K11A/E21K. However, the actual magnitude of the RT defect is much
less, given that R10A/K11A mutant virions are impaired for RNA
packaging and therefore contain less template for DNA synthesis.
Indeed, in our assays, virions were normalized for protein content and
do not account for differences in RNA packaging. If one corrects the
results obtained by real-time PCR for the amount of viral genomic RNA
packaged into mutant virions, the reduction in DNA synthesis by mutant
R10A/K11A is only twofold compared to the wild-type level. Thus, mutant
R10A/K11A virions infect cells and reverse transcribe to
quasi-wild-type levels. This finding is in agreement with the
observation that endo-RT is essentially normal in our mutants, and it
also suggests that tRNA3Lys placement and dimeric RNA
formation are not affected in our NC mutant.
Formation of 2-LTR circles was found to be reduced to the same extent
as full-length viral DNA, suggesting that nuclear import of the
preintegration complex (PIC) occurs normally in cells infected with the
R10A/K11A mutant. 2-LTR circles are not believed to be substrates for
integration (10, 18, 23, 43, 51) but are considered markers
of successful nuclear important because they result from ligation of
full-length viral DNA by cellular DNA ligases that localize in the
nucleus (3, 24, 65, 66, 70). Our quantitation of 2-LTR
circles was performed with dividing Jurkat T cells, and so it remains
possible that a nuclear import defect would be detected after infection
of a nondividing cell such as a macrophage.
Since RT and nuclear import in Jurkat T cells are hardly affected in
the R10A/K11A mutant, a defect in a subsequent step must be invoked to
explain the 100-fold reduction in infectivity in MAGI assays (or at
least a 10-fold reduction if one considers the 5-fold packaging defect
and 2-fold RT defect). We believe this defective step to be
integration. A role for NC in integration has been proposed based on in
vitro assays (15, 16) and based on the finding that certain
NC zinc finger mutants exhibit a defect in vivo, after nuclear
translocation of viral DNA (36, 37).
How NC might affect integration is unclear, especially since NC's
presence in purified PICs is not agreed on by all investigators (25, 32). NC might act directly on the integration reaction, as recently proposed by others (16), by facilitating DNA
condensation and/or DNA melting, conditions that promote integration
(7, 12, 56, 61). NC might maintain the integrity of viral
DNA; M-MuLV NC mutants have been shown to synthesize 2-LTR circles containing large deletions and insertions at the junctions
(36). A limited analysis of the sequence of the 2-LTR circle
junctions produced by our R10A/K11A mutant, however, showed no obvious
differences from the wild type (data not shown).
Alternatively, the effect of NC on integration might be indirect, being
exerted, for example, by regulating viral protease processing of PIC
components. The only evidence for a protease processing defect in
mutant R10A/K11A is the accumulation of incompletely processed CA, as
processing at other sites appears normal (17a). How this
would affect integration is unclear, since only traces amounts of CA
are found in highly purified PICs, questioning their relevance in the
integration process (55). Last, although we believe that
mutant R10A/K11A exhibits a defect in integration, it is also possible
that our mutant is affected at an as yet uncharacterized step that
occurs after nuclear translocation of viral DNA.
The presence of the second-site change E21K compensates for all of the
defects that were observed with the R10A/K11A mutation. In the solution
structure of wild-type HIV-1 NC complexed with the HIV-1 SL3 stem-loop
RNA, NC residues R10 and K11 lie on a 310 helix and contact
phosphodiester groups on the RNA (21). Interestingly,
residue E21 lies on the same face of NC as R10 and K11, where it
contacts residue K14 and is believed to stabilize the first zinc finger
(Fig. 9). Requirement for this
stabilization must not be absolute, since residue E21 can be mutated in
the context of otherwise wild-type proviral DNA without an appreciable defect in virion replication, in agreement with a previous study (22). However, a significant proportion (~10%) of E21K
virions have multiple core structures, and this may be related to a
destabilizing effect of the mutation on the first zinc-finger. How an
NC mutation would induce the production of virions with multiple cores
is unknown. Clearly though, NC is present when the core assembly process is initiated and, interestingly, successful attempts to induce
conical core formation in vitro have utilized a Gag fusion protein that
encompasses CA and NC (13, 33, 38).

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 9.
Ribbon diagram (left) and space-filling image (right) of
the HIV-1 NC-SL3 -RNA complex (21). NC is shown in
purple. Residues R10/K11 and E21 are shown in green and red,
respectively. SL3 RNA is shown in white. Cysteine and histidine
residues participating in the two Cys-His boxes are shown in yellow on
the left.
|
|
A complete understanding of how E21K rescues R10A/K11A replication will
require the determination of the structure of these mutants. The E21K
mutation might rescue replication by restoring local positive charge,
thus reestablishing contacts with the RNA phosphodiester groups that
had been disrupted by the R10A/K11A mutation. Alternatively, the
effects of E21K might be less specific and the mutation might simply
serve to restore the net positive charge of NC above a critical
threshold required for nonspecific RNA binding. The latter possibility
seems unlikely given that several HIV-1 NC mutants in which two basic
residues are mutated to alanine are able to replicate to wild-type
levels (60). In either case, the identification of E21K as a
second-site suppressor of R10A/K11A underlines the importance of NC
basic residues for HIV-1 replication.
 |
ACKNOWLEDGMENTS |
We thank Anna Aldovini for generously providing plasmid DNA. We
thank Cagan Gurer for critical reading of the manuscript and Douglas
Brateen and Leondios Kostrykis for technical assistance with the
real-time PCR. We are indebted to Mohammed Asmal for graphic work.
This work was supported by grant AI 41857 (J.L.) and by shared core
facilities of the Columbia-Rockefeller Center for AIDS Research (P30
AI42848), both from the National Institutes of Health, and by contract
975313 from the Swedish Cancer Foundation (S.H.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Departments of
Microbiology and Medicine, Columbia University College of Physicians and Surgeons, 701 W. 168th St., New York, NY 10032. Phone: (212) 305-8706. Fax: (212) 305-0333. E-mail: jl45{at}columbia.edu.
 |
REFERENCES |
| 1.
|
Allain, B.,
M. Lapadat-Tapolsky,
C. Berlioz, and J. L. Darlix.
1994.
Transactivation of the minus-strand DNA transfer by nucleocapsid protein during reverse transcription of the retroviral genome.
EMBO J.
13:973-981[Medline].
|
| 2.
|
Allain, B.,
J. B. Rascle,
H. de Rocquigny,
B. Roques, and J. L. Darlix.
1998.
CIS elements and trans-acting factors required for minus strand DNA transfer during reverse transcription of the genomic RNA of murine leukemia virus.
J. Mol. Biol.
277:225-235[CrossRef][Medline].
|
| 3.
|
Ansari-Lari, M. A.,
L. A. Donehower, and R. A. Gibbs.
1995.
Analysis of human immunodeficiency virus type 1 integrase mutants.
Virology
213:680[CrossRef][Medline].
|
| 4.
|
Bennett, R. P.,
T. D. Nelle, and J. W. Wills.
1993.
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus Gag proteins.
J. Virol.
67:6487-6498[Abstract/Free Full Text].
|
| 5.
|
Berkowitz, R.,
J. Fisher, and S. P. Goff.
1996.
RNA packaging.
Curr. Top. Microbiol. Immunol.
214:177-218[Medline].
|
| 6.
|
Berthoux, L.,
C. Pechoux,
M. Ottmann,
G. Morel, and J. L. Darlix.
1997.
Mutations in the N-terminal domain of human immunodeficiency virus type 1 nucleocapsid protein affect virion core structure and proviral DNA synthesis.
J. Virol.
71:6973-6981[Abstract].
|
| 7.
|
Bor, Y. C.,
F. D. Bushman, and L. E. Orgel.
1995.
In vitro integration of human immunodeficiency virus type 1 cDNA into targets containing protein-induced bends.
Proc. Natl. Acad. Sci. USA
92:10334-10338[Abstract/Free Full Text].
|
| 8.
|
Borroto-Esoda, K., and L. R. Boone.
1991.
Equine infectious anemia virus and human immunodeficiency virus DNA synthesis in vitro: characterization of the endogenous reverse transcriptase reaction.
J. Virol.
65:1952-1959[Abstract/Free Full Text].
|
| 9.
|
Braaten, D.,
E. K. Franke, and J. Luban.
1996.
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 prior to the initiation of reverse transcription.
J. Virol.
70:3551-3560[Abstract].
|
| 10.
|
Brown, P. O.,
B. Bowerman,
H. E. Varmus, and J. M. Bishop.
1987.
Correct integration of retroviral DNA in vitro.
Cell
49:347-356[CrossRef][Medline].
|
| 11.
|
Burniston, M. T.,
A. Cimarelli,
J. Colgan,
S. P. Curtis, and J. Luban.
1999.
Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein.
J. Virol.
73:8527-8540[Abstract/Free Full Text].
|
| 12.
|
Bushman, F. D., and R. Craigie.
1992.
Integration of human immunodeficiency virus DNA: adduct interference analysis of required DNA sites.
Proc. Natl. Acad. Sci. USA
89:3458-3462[Abstract/Free Full Text].
|
| 13.
|
Campbell, S., and A. Rein.
1999.
In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain.
J. Virol.
73:2270-2279[Abstract/Free Full Text].
|
| 14.
|
Carriere, C.,
B. Gay,
N. Chazal,
N. Morin, and P. Boulanger.
1995.
Sequence requirements for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles.
J. Virol.
69:2366-2377[Abstract].
|
| 15.
|
Carteau, S.,
S. C. Batson,
L. Poljak,
J. F. Mouscadet,
H. de Rocquigny,
J. L. Darlix,
B. P. Roques,
E. Kas, and C. Auclair.
1997.
Human immunodeficiency virus type 1 nucleocapsid protein specifically stimulates Mg2+-dependent DNA integration in vitro.
J. Virol.
71:6225-6229[Abstract].
|
| 16.
|
Carteau, S.,
R. J. Gorelick, and F. D. Bushman.
1999.
Coupled integration of human immunodeficiency virus type 1 cDNA ends by purified integrase in vitro: stimulation by the viral nucleocapsid protein.
J. Virol.
73:6670-6679[Abstract/Free Full Text].
|
| 17.
|
Cimarelli, A., and J. Luban.
1999.
Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein.
J. Virol.
73:5388-5401[Abstract/Free Full Text].
|
| 17a.
|
Cimarelli, A.,
S. Sandin,
S. Höglund, and J. Luban.
2000.
Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA.
J. Virol.
74:3046-3057[Abstract/Free Full Text].
|
| 18.
|
Craigie, R.,
T. Fujiwara, and F. Bushman.
1990.
The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro.
Cell
62:829-837[CrossRef][Medline].
|
| 19.
|
Darlix, J. L.,
M. Lapadat-Tapolsky,
H. de Rocquigny, and B. P. Roques.
1995.
First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses.
J. Mol. Biol.
254:523-537[CrossRef][Medline].
|
| 20.
|
Dawson, L., and X. F. Yu.
1998.
The role of nucleocapsid of HIV-1 in virus assembly.
Virology
251:141-157[CrossRef][Medline].
|
| 21.
|
De Guzman, R. N.,
Z. R. Wu,
C. C. Stalling,
L. Pappalardo,
P. N. Borer, and M. F. Summers.
1998.
Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element.
Science
279:384-388[Abstract/Free Full Text].
|
| 22.
|
Dorfman, T.,
J. Luban,
S. P. Goff,
W. A. Haseltine, and H. G. Gottlinger.
1993.
Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein.
J. Virol.
67:6159-6169[Abstract/Free Full Text].
|
| 23.
|
Ellis, J., and A. Bernstein.
1989.
Retrovirus vectors containing an internal attachment site: evidence that circles are not intermediates to murine retrovirus integration.
J. Virol.
63:2844-2846[Abstract/Free Full Text].
|
| 24.
|
Engelman, A.,
G. Englund,
J. M. Orenstein,
M. A. Martin, and R. Craigie.
1995.
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication.
J. Virol.
69:2729-2736[Abstract].
|
| 25.
|
Farnet, C. M., and F. D. Bushman.
1997.
HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro.
Cell
88:483-492[CrossRef][Medline].
|
| 26.
|
Feng, Y. X.,
S. Campbell,
D. Harvin,
B. Ehresmann,
C. Ehresmann, and A. Rein.
1999.
The human immunodeficiency virus type 1 Gag polyprotein has nucleic acid chaperone activity: possible role in dimerization of genomic RNA and placement of tRNA on the primer binding site.
J. Virol.
73:4251-4256[Abstract/Free Full Text].
|
| 27.
|
Feng, Y. X.,
T. D. Copeland,
L. E. Henderson,
R. J. Gorelick,
W. J. Bosche,
J. G. Levin, and A. Rein.
1996.
HIV-1 nucleocapsid protein induces "maturation" of dimeric retroviral RNA in vitro.
Proc. Natl. Acad. Sci. USA
93:7577-7581[Abstract/Free Full Text].
|
| 28.
|
Franke, E. K.,
H. E. H. Yuan,
K. L. Bossolt,
S. P. Goff, and J. Luban.
1994.
Specificity and sequence requirements for interactions between various retroviral Gag proteins.
J. Virol.
68:5300-5305[Abstract/Free Full Text].
|
| 29.
|
Freed, E. O.
1998.
HIV-1 gag proteins: diverse functions in the virus life cycle.
Virology
251:1-15[CrossRef][Medline].
|
| 30.
|
Fu, W.,
R. J. Gorelick, and A. Rein.
1994.
Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions.
J. Virol.
68:5013-5018[Abstract/Free Full Text].
|
| 31.
|
Fu, W., and A. Rein.
1993.
Maturation of dimeric viral RNA of Moloney murine leukemia virus.
J. Virol.
67:5443-5449[Abstract/Free Full Text].
|
| 32.
|
Gallay, P.,
S. Swingler,
J. Song,
F. Bushman, and D. Trono.
1995.
HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase.
Cell
83:569-576[CrossRef][Medline].
|
| 33.
|
Ganser, B. K.,
S. Li,
V. Y. Klishko,
J. T. Finch, and W. I. Sundquist.
1999.
Assembly and analysis of conical models for the HIV-1 core.
Science
283:80-83[Abstract/Free Full Text].
|
| 34.
|
Gheysen, D.,
E. Jacobs,
F. de Foresta,
C. Thiriart,
M. Francotte,
D. Thines, and M. DeWilde.
1989.
Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells.
Cell
59:103-112[CrossRef][Medline].
|
| 35.
|
Goncalves, J.,
Y. Korin,
J. Zack, and D. Gabuzda.
1996.
Role of Vif in human immunodeficiency virus type 1 reverse transcription.
J. Virol.
70:8701-8709[Abstract].
|
| 36.
|
Gorelick, R. J.,
W. Fu,
T. D. Gagliardi,
W. J. Bosche,
A. Rein,
L. E. Henderson, and L. O. Arthur.
1999.
Characterization of the block in replication of nucleocapsid protein zinc finger mutants from Moloney murine leukemia virus.
J. Virol.
73:8185-8195[Abstract/Free Full Text].
|
| 37.
|
Gorelick, R. J.,
T. D. Gagliardi,
W. J. Bosche,
T. A. Wiltrout,
L. V. Coren,
D. J. Chabot,
J. D. Lifson,
L. E. Henderson, and L. O. Arthur.
1999.
Strict conservation of the retroviral nucleocapsid protein zinc finger is strongly influenced by its role in viral infection processes: characterization of HIV-1 particles containing mutant nucleocapsid zinc-coordinating sequences.
Virology
256:92-104[CrossRef][Medline].
|
| 38.
|
Gross, I.,
H. Hohenberg, and H. G. Krausslich.
1997.
In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus.
Eur. J. Biochem.
249:592-600[Medline].
|
| 39.
|
Guo, J.,
L. E. Henderson,
J. Bess,
B. Kane, and J. G. Levin.
1997.
Human immunodeficiency virus type 1 nucleocapsid protein promotes efficient strand transfer and specific viral DNA synthesis by inhibiting TAR-dependent self-priming from minus-strand strong-stop DNA.
J. Virol.
71:5178-5188[Abstract].
|
| 40.
|
Hirt, B.
1967.
Selective extraction of polyomavirus DNA from infected mouse cell cultures.
J. Mol. Biol.
26:365-369[CrossRef][Medline].
|
| 41.
|
Housset, V.,
H. De Rocquigny,
B. P. Roques, and J. L. Darlix.
1993.
Basic amino acids flanking the zinc finger of Moloney murine leukemia virus nucleocapsid protein NCp10 are critical for virus infectivity.
J. Virol.
67:2537-2545[Abstract/Free Full Text].
|
| 42.
|
Jowett, J. B.,
D. J. Hockley,
M. V. Nermut, and I. M. Jones.
1992.
Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation.
J. Gen. Virol.
73:3079-3086[Abstract/Free Full Text].
|
| 43.
|
Katz, R. A.,
G. Merkel,
J. Kulkosky,
J. Leis, and A. M. Skalka.
1990.
The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro.
Cell
63:87-95[CrossRef][Medline].
|
| 44.
|
Kiernan, R. E.,
A. Ono,
G. Englund, and E. O. Freed.
1998.
Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle.
J. Virol.
72:4116-4126[Abstract/Free Full Text].
|
| 45.
|
Kimpton, J., and M. Emerman.
1992.
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated -galactosidase gene.
J. Virol.
66:2232-2239[Abstract/Free Full Text].
|
| 46.
|
Kostrikis, L. G.,
S. Tyagi,
M. M. Mhlanga,
D. D. Ho, and F. R. Kramer.
1998.
Spectral genotyping of human alleles.
Science
279:1228-1229[Free Full Text].
|
| 47.
|
Krausslich, H. G., and R. Welker.
1996.
Intracellular transport of retroviral capsid components.
Curr. Top. Microbiol. Immunol.
214:25-63[Medline].
|
| 48.
|
Lapadat-Tapolsky, M.,
H. De Rocquigny,
D. Van Gent,
B. Roques,
R. Plasterk, and J. L. Darlix.
1993.
Interactions between HIV-1 nucleocapsid protein and viral DNA may have important functions in the viral life cycle.
Nucleic Acids Res.
21:831-839[Abstract/Free Full Text].
|
| 49.
|
Lener, D.,
V. Tanchou,
B. P. Roques,
S. F. Le Grice, and J. L. Darlix.
1998.
Involvement of HIV-I nucleocapsid protein in the recruitment of reverse transcriptase into nucleoprotein complexes formed in vitro.
J. Biol. Chem.
273:33781-33786[Abstract/Free Full Text].
|
| 50.
|
Lewin, S. R.,
M. Vesanen,
L. Kostrikis,
A. Hurley,
M. Duran,
L. Zhang,
D. D. Ho, and M. Markowitz.
1999.
Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy.
J. Virol.
73:6099-6103[Abstract/Free Full Text].
|
| 51.
|
Lobel, L. I.,
J. E. Murphy, and S. P. Goff.
1989.
The palindromic LTR-LTR junction of Moloney murine leukemia virus is not an efficient substrate for proviral integration.
J. Virol.
63:2629-2637[Abstract/Free Full Text].
|
| 52.
|
Mak, J.,
M. Jiang,
M. A. Wainberg,
M. L. Hammarskjold,
D. Rekosh, and L. Kleiman.
1994.
Role of Pr160gag-pol in mediating the selective incorporation of tRNALys into human immunodeficiency virus type 1 particles.
J. Virol.
68:2065-2072[Abstract/Free Full Text].
|
| 53.
|
Mak, J.,
A. Khorchid,
Q. Cao,
Y. Huang,
I. Lowy,
M. A. Parniak,
V. R. Prasad,
M. A. Wainberg, and L. Kleiman.
1997.
Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-pol incorporation into HIV-1.
J. Mol. Biol.
265:419-431[CrossRef][Medline].
|
| 54.
|
McDermott, J.,
L. Farrell,
R. Ross, and E. Barklis.
1996.
Structural analysis of human immunodeficiency virus type 1 Gag protein interactions, using cysteine-specific reagents.
J. Virol.
70:5106-5114[Abstract/Free Full Text].
|
| 55.
|
Miller, M. D.,
C. M. Farnet, and F. D. Bushman.
1997.
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition.
J. Virol.
71:5382-5390[Abstract].
|
| 56.
|
Muller, H. P., and H. E. Varmus.
1994.
DNA bending creates favored sites for retroviral integration: an explanation for preferred insertion sites in nucleosomes.
EMBO J.
13:4704-4714[Medline].
|
| 57.
|
Myers, G.,
B. Korber,
S. Wain-Hobson,
K.-T. Jeang,
L. E. Henderson, and G. N. Pavlakis.
1994.
Human retroviruses and AIDS.
Los Alamos National Laboratory, Los Alamos, N. Mex.
|
| 58.
|
Ottmann, M.,
C. Gabus, and J. L. Darlix.
1995.
The central globular domain of the nucleocapsid protein of human immunodeficiency virus type 1 is critical for virion structure and infectivity.
J. Virol.
69:1778-1784[Abstract].
|
| 59.
|
Peliska, J. A.,
S. Balasubramanian,
D. P. Giedroc, and S. J. Benkovic.
1994.
Recombinant HIV-1 nucleocapsid protein accelerates HIV-1 reverse transcriptase catalyzed DNA strand transfer reactions and modulates RNase H activity.
Biochemistry
33:13817-13823[CrossRef][Medline].
|
| 60.
|
Poon, D. T.,
J. Wu, and A. Aldovini.
1996.
Charged amino acid residues of human immunodeficiency virus type 1 nucleocapsid p7 protein involved in RNA packaging and infectivity.
J. Virol.
70:6607-6616[Abstract/Free Full Text].
|
| 61.
|
Pruss, D.,
F. D. Bushman, and A. P. Wolffe.
1994.
Human immunodeficiency virus integrase directs integration to sites of severe DNA distortion within the nucleosome core.
Proc. Natl. Acad. Sci. USA
91:5913-5917[Abstract/Free Full Text].
|
| 62.
|
Rascle, J. B.,
D. Ficheux, and J. L. Darlix.
1998.
Possible roles of nucleocapsid protein of MoMuLV in the specificity of proviral DNA synthesis and in the genetic variability of the virus.
J. Mol. Biol.
280:215-225[CrossRef][Medline].
|
| 63.
|
Rein, A.
1994.
Retroviral RNA packaging: a review.
Arch. Virol. Suppl.
9:513-522[Medline].
|
| 64.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 65.
|
Shank, P. R., and H. E. Varmus.
1978.
Virus-specific DNA in the cytoplasm of avian sarcoma virus-infected cells is a precursor to covalently closed circular viral DNA in the nucleus.
J. Virol.
25:104-114[Abstract/Free Full Text].
|
| 66.
|
Swanstrom, R.,
W. J. DeLorbe,
J. M. Bishop, and H. E. Varmus.
1981.
Nucleotide sequence of cloned unintegrated avian sarcoma virus DNA: viral DNA contains direct and inverted repeats similar to those in transposable elements.
Proc. Natl. Acad. Sci. USA
78:124-128[Abstract/Free Full Text].
|
| 67.
|
Tanchou, V.,
C. Gabus,
V. Rogemond, and J. L. Darlix.
1995.
Formation of stable and functional HIV-1 nucleoprotein complexes in vitro.
J. Mol. Biol.
252:563-571[CrossRef][Medline].
|
| 68.
|
Tsuchihashi, Z., and P. O. Brown.
1994.
DNA strand exchange and selective DNA annealing promoted by the human immunodeficiency virus type 1 nucleocapsid protein.
J. Virol.
68:5863-5870[Abstract/Free Full Text].
|
| 69.
|
Weiss, A.,
R. Wiskocil, and J. Stobo.
1984.
The role of T3 surface molecules in the activation of human T cells: a two stimulus requirement for IL-2 production reflects events occurring at a pretranslational level.
J. Immunol.
133:123-128[Abstract].
|
| 70.
|
Wiskerchen, M., and M. A. Muesing.
1995.
Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells.
J. Virol.
69:376-386[Abstract].
|
| 71.
|
You, J. C., and C. S. McHenry.
1994.
Human immunodeficiency virus nucleocapsid protein accelerates strand transfer of the terminally redundant sequences involved in reverse transcription.
J. Biol. Chem.
269:31491-31495[Abstract/Free Full Text].
|
Journal of Virology, May 2000, p. 4273-4283, Vol. 74, No. 9
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.